Skip to content

The effect of estrogen and misoprostol on abortion

Comparison of induction of abortion in the first trimester using misoprostol and misoprostol with estrogen priming

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017070934981N1
Enrollment
100
Registered
2017-07-16
Start date
2017-07-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion. Early fetal death with retention of dead fetus

Interventions

In this study, the aim of this study was to examine the induction of abortion in the first trimester using misoprostol and misoprostol with estrogen priming, randomly divided into two groups receiving
Treatment - Drugs

Sponsors

Vice chancellor for research, Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Entry Criteria: Pregnant women aged 6 weeks to 14 weeks have two Missed Abortion ultrasounds. Exit criteria: history of cesarean section, history of adrenal, kidney or liver disease, pulmonary disease, coagulation disorders, evidence of thromboembolic events, prostaglandin sensitivity, smoking, water repellent, vaginal bleeding, history of thromboembolism, estrogen dependent cancers Breast and genital system), intrauterine device, any normal amount of blood. Pre-treatment blood tests include CBC, liver and kidney function tests including blood urea, creatinine, albumin, globulin, liver enzymes, electrolytes, severe anemia, disorders Uncontrolled seizures

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Successful abortion. Timepoint: 4 hours after disposal of pregnancy. Method of measurement: Based on the amount of pregnancy residues in ultrasound after excretion of pregnancy products.

Secondary

MeasureTime frame
Misoprostol side effects. Timepoint: Immediately after starting treatment. Method of measurement: Based on completed patient questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Esmaeilpour

Zahedan University of Medical Sciences

esmailpoorm2@yahoo.com+98 543329557185

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026